EUCTR2017-004972-74-GR进行中（未招募）1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
Amgen Inc.0 个研究点目标入组 16 人开始时间: 2020年12月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject's legally acceptable representative has provided informed
- •consent and the subject has provided written assent based on local
- •regulations and/or guidelines prior to initiation of any study-specific
- •activities/procedures
- •Ambulatory male or female children 5 to less than 12 years of age
- •(cohorts 2,4, and 6) or adolescents 12 to less than 18 years of age
- •(cohorts 1, 3 and 5) upon entry into screening
- •Clinical diagnosis of OI defined as a clinical history consistent with type
- •I-IV OI as determined by presence of expected phenotype (eg, facial
- •shape, voice, blue sclera, dentinogenesis imperfecta, typical radiographic
- •features, fracture pattern) and lack of additional features unrelated to
- •type I-IV OI (eg, blindness, mental retardation, neuropathy,
- •craniosynostosis, premature exfoliation of deciduous teeth)
- •If familial, also must be autosomal dominant
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of an electrophoresis pattern inconsistent with type I to type IV
- •History of known mutation in a gene other than collagen type I
- •alpha/collagen type I alpha 2 (COL1AI/COL1A2) causing OI or other
- •metabolic bone disease
- •History of congenital dislocation of the radial head, interosseous
- •membrane calcification, or exuberant callus formation
- •History of osteomalacia or rickets
- •Body weight less than 10 kg or greater than 90 kg
- •History of other bone diseases that affect bone metabolism (eg,
- •osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis,
- •osteopetrosis, hypophosphatasia)
- •History of Kawasaki disease, rheumatic myocarditis, ischemic
- •cardiomyopathy, inherited cardiomyopathies, valvular heart disease,
- •nephrotic syndrome, familial hypercholesterolemia, stroke, or any
- •thromboembolic disorder
- •Evidence of untreated or unhealed oral cavities or oral infections
- •Unhealed or planned invasive dental or tooth procedure; removal of baby
- •teeth is acceptable and not considered an invasive dental procedure
- •Unhealed fracture as defined by orthopedic opinion
- •Osteotomy, rodding surgery or spinal fusion surgery within 5 months
- •prior to screening, or not yet healed per orthopedic surgeon
- •Any planned major surgery, including skeletal surgery (eg, rodding
- •surgery, spinal surgery) within the next 6 months from Day 1 that would
- •interfere with study procedures or would require missing of any IP
- •Symptoms associated with skull abnormalities such as basilar
- •invagination, basilar impression or Chiari malformation (headache
- •induced by coughing or straining for stool, or parasthesia or weakness)
- •History of malabsorption (in children with serum albumin < lower limit
- •normal [LLN]), malabsorption should be clinically ruled out by the
- •investigator to confirm eligibility)
- •History of long QT syndrome
- •History of malignancy
- •History of any solid organ or bone marrow transplant
- •Positive blood screen for hepatitis B surface antigen (HbsAg), hepatitis B
- •core antibody (HBcAb), or hepatitis C antibody (HepCAb), human
- •immunodeficiency virus (HIV) -1 or -2 antibody
- •History of hyper- or hypothyroidism, unless subject is on stable therapy
- •> 6 months and has supporting laboratory documentation within 6
- •months prior to or at screening indicating normal serum thyroidstimulating
- •hormone [TSH] value
- •Evidence of any of the following:
- •Current hyper- or hypoparathyroidism (parathyroid hormone outside the
- •normal range)
- •Renal disease: Estimated glomerular filtration rate (eGFR) < 60
- •mL/min/1.73 m2 (calculated by the bedside Schwartz equation at
- •eGFR (mL/min/1.73 m2)= 0.413 X (height/serum creatinine)
- •(Height is in centimeters, and serum creatinine is in mg/dL)
- •Current hypocalcemia (albumin-adjusted serum calcium < LLN of the
- •laboratory's reference range) or hypercalcemia (albumin-adjusted serum
- •calcium > ULN of the laboratory's reference range) at the time of
- 另有 12 项未显示
研究者
相似试验
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaEUCTR2017-004972-74-DEAmgen Inc.24
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaEUCTR2017-004972-74-HUAmgen Inc.16
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaEUCTR2017-004972-74-ATAmgen Inc.24
进行中（未招募）
1 期
An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis ImperfectaEUCTR2017-004972-74-ITAMGEN INC.24
进行中（未招募）
1 期
Study to test the safety and tolerability of different doses (amounts) of sepofarsen (an RNA therapy) in children of age 3 to less than 8 years that have CEP290 mediated Leber Congenital Amaurosis 10 (LCA10) due to the c.2991+1655A>G mutatioeber Congenital Amaurosis 10 (LCA10) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 GeneMedDRA version: 20.0Level: PTClassification code 10070667Term: Leber's congenital amaurosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-000535-45-GBProQR Therapeutics10